Effects of Replacing a Central Glycine Residue in GLP-1 on Receptor Affinity and Signaling Profile

Overview

Journal Chembiochem

Specialty Biochemistry

Date 2023 Aug 25

PMID 37624685

Authors

Kyle A Brown

Samuel H Gellman

Affiliations

Soon will be listed here.

Abstract

Agonists of the glucagon-like peptide-1 receptor (GLP-1R) are used to treat diabetes and obesity. Cryo-EM structures indicate that GLP-1 is completely α-helical when bound to the GLP-1R. The mature form of this hormone, GLP-1(7-36), contains a glycine residue near the center (Gly22). Since glycine has the second-lowest α-helix propensity among the proteinogenic α-amino acid residues, and Gly22 does not appear to make direct contact with the receptor, we were motivated to explore the impact on agonist activity of altering the α-helix propensity at this position. We examined GLP-1 analogues in which Gly22 was replaced with L-Ala, D-Ala, or β-amino acid residues with varying helix propensities. The results suggest that the receptor is reasonably tolerant of variations in helix propensity, and that the functional receptor-agonist complex may comprise a conformational spectrum rather than a single fixed structure.

References

Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y . G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021; 6(1):7. PMC: 7790836. DOI: 10.1038/s41392-020-00435-w. View

Fisher B, Hong S, Gellman S . Helix Propensities of Amino Acid Residues via Thioester Exchange. J Am Chem Soc. 2017; 139(38):13292-13295. PMC: 5995559. DOI: 10.1021/jacs.7b07930. View

Adelhorst K, Hedegaard B, Knudsen L, Kirk O . Structure-activity studies of glucagon-like peptide-1. J Biol Chem. 1994; 269(9):6275-8. View

Seth Horne W, Johnson L, Ketas T, Klasse P, Lu M, Moore J . Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A. 2009; 106(35):14751-6. PMC: 2736470. DOI: 10.1073/pnas.0902663106. View

Hager M, Clydesdale L, Gellman S, Sexton P, Wootten D . Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1. Biochem Pharmacol. 2017; 136:99-108. PMC: 5794489. DOI: 10.1016/j.bcp.2017.03.018. View

Cary B, Deganutti G, Zhao P, Truong T, Piper S, Liu X . Structural and functional diversity among agonist-bound states of the GLP-1 receptor. Nat Chem Biol. 2021; 18(3):256-263. PMC: 8950777. DOI: 10.1038/s41589-021-00945-w. View

Jastreboff A, Aronne L, Ahmad N, Wharton S, Connery L, Alves B . Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3):205-216. DOI: 10.1056/NEJMoa2206038. View

Zhang X, Belousoff M, Zhao P, Kooistra A, Truong T, Ang S . Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020; 80(3):485-500.e7. DOI: 10.1016/j.molcel.2020.09.020. View

Fisher B, Hong S, Gellman S . Thermodynamic Scale of β-Amino Acid Residue Propensities for an α-Helix-like Conformation. J Am Chem Soc. 2018; 140(30):9396-9399. PMC: 6095142. DOI: 10.1021/jacs.8b05162. View

10.

Muller T, Finan B, Bloom S, DAlessio D, Drucker D, Flatt P . Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30:72-130. PMC: 6812410. DOI: 10.1016/j.molmet.2019.09.010. View

11.

Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q . Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature. 2017; 546(7657):248-253. PMC: 5587415. DOI: 10.1038/nature22394. View

12.

Kim W, Egan J . The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4):470-512. PMC: 2696340. DOI: 10.1124/pr.108.000604. View

13.

Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J . Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015; 58(18):7370-80. DOI: 10.1021/acs.jmedchem.5b00726. View

14.

Hilger D, Kumar K, Hu H, Pedersen M, OBrien E, Giehm L . Structural insights into differences in G protein activation by family A and family B GPCRs. Science. 2020; 369(6503). PMC: 7954662. DOI: 10.1126/science.aba3373. View

15.

Cary B, Hager M, Gellman S . Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues. Chembiochem. 2019; 20(22):2834-2840. PMC: 6861653. DOI: 10.1002/cbic.201900300. View

16.

Seth Horne W, Price J, Gellman S . Interplay among side chain sequence, backbone composition, and residue rigidification in polypeptide folding and assembly. Proc Natl Acad Sci U S A. 2008; 105(27):9151-6. PMC: 2453709. DOI: 10.1073/pnas.0801135105. View

17.

Zhang H, Sturchler E, Zhu J, Nieto A, Cistrone P, Xie J . Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects. Nat Commun. 2015; 6:8918. PMC: 4686834. DOI: 10.1038/ncomms9918. View

18.

Harmar A . Family-B G-protein-coupled receptors. Genome Biol. 2002; 2(12):REVIEWS3013. PMC: 138994. DOI: 10.1186/gb-2001-2-12-reviews3013. View

19.

Andersen N, Brodsky Y, Neidigh J, Prickett K . Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorg Med Chem. 2001; 10(1):79-85. DOI: 10.1016/s0968-0896(01)00263-2. View

20.

Pierce K, Premont R, Lefkowitz R . Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002; 3(9):639-50. DOI: 10.1038/nrm908. View